▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1994 by analyst upside · 2026-09-27
IRMD
IRADIMED CORPORATION
Healthcare · Market Cap $1B · P/E 47.9x
ANALYST PRICE TARGET
+37.6%
implied upside to consensus target
Current Price $85.76
Consensus Target $118.0
Bull Target $120.0
Bear Target $116.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
1
Sell
0
52-Week Low $67.84
52-Week High $107.9
YTD Return -9.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 47.9x
Forward P/E 35.0x
EPS (TTM) $1.79
PEG Ratio N/A
Dividend Yield 0.93%
Revenue (TTM) $86M
Profit Margin 26.7%
52-WEEK RANGE
52-Week Low $67.84
52-Week High $107.9
Current Price $85.76
Bear Target $116.0
Bull Target $120.0
● Now $85.76 ● Target $118.0
TRADING DATA
Avg Volume 125K
YTD Return -9.6%
Analyst Count 2
Consensus Buy
Upside to Target +37.6%
Last Updated 2026-09-27

ANALYST SUMMARY

IRADIMED CORPORATION (IRMD) is currently trading at $85.76 with a Wall Street consensus price target of $118.0, implying potential upside of 37.6% over the next 12 months. 2 analysts currently cover IRMD, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $120.0, while the most cautious has a target of $116.0.

IRMD operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 9.6% year-to-date and is currently trading near the lower end of its 52-week range of $67.84 – $107.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GDRX +17.9%
GoodRx Holdings, Inc.
$1B · P/E 55.8x · Hold
HSTM +18.6%
HealthStream, Inc.
$890M · P/E 40.4x · Buy
PNTG +14.5%
The Pennant Group, Inc.
$1B · P/E 44.8x · Buy
OMDA +44.5%
Omada Health, Inc.
$1B · P/E 29.3x · Buy
OMCL +71.9%
Omnicell, Inc.
$2B · P/E 40.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IRMD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Needham ● Initiated
Hold 2026-09-22 20% win rate (5 calls)
Freedom Broker ● Initiated
Buy 2026-04-02 Building track record
Roth MKM reit
Buy → Buy 2025-02-14 25% win rate (12 calls)
Roth MKM - Reiterated
Buy → Buy 2024-08-02 25% win rate (12 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
8/30
Consensus clarity
29/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →